Dual risk of anticholinergic burden and CSF alzheimer's biomarkers in older patients: a mortality follow-up study from daily medical practice.

ABSTRACT:

Background

Anticholinergic medications are widely prescribed to older adults and are linked to increased mortality and cognitive decline. Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD)-amyloid and tau-are strong prognostic indicators in neurocognitive disorders (NCD). However, it remains unclear whether anticholinergic burden amplifies mortality risk depending on CSF biomarker profiles in cognitively impaired individuals.

Methods

We conducted a retrospective monocentric study of 927 patients aged ≥ 65 years with mild or major NCD from a tertiary memory clinic in Paris, France. Participants underwent CSF biomarker assessment for amyloid (A), phosphorylated tau (T), and total tau (N), and were classified into ATN profiles. Anticholinergic burden was evaluated

SUBMITTER: Decaix T 

PROVIDER: S-EPMC12261860 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature